Kopran Subsidiary Plans Rights Issue, Appoints Independent Director

Kopran Ltd. reported its consolidated revenue at ₹345.66 crore and profit after tax at ₹24.18 crore for the quarter ending March 31, 2024.

In parallel, Kopran Research Laboratories Limited (KRLL), a subsidiary of Kopran Ltd., has received board approval for a ₹18.75 crore rights issue. This capital raise is aimed at strengthening the subsidiary's working capital.

The rights issue will offer one new share for every 12 shares held by existing shareholders. Shares are set to be issued at a premium, with a face value of ₹10 and a premium of ₹90 per share.

Alongside the proposed capital raise, the KRLL board has appointed Mr. Chandresh Gandhi as an Additional Director. Mr. Gandhi, a Chartered Accountant, will serve a five-year term as a Non-Executive, Independent Director.

This capital infusion is intended to boost KRLL's working capital, potentially improving its operational efficiency and supporting its research and development initiatives. Mr. Gandhi's appointment is expected to bring valuable experience and strategic guidance to the subsidiary's board.

Kopran Ltd. operates as a pharmaceutical company focused on Active Pharmaceutical Ingredients (APIs) and finished formulations, with KRLL playing a role in its R&D activities.

The success of both the rights issue and Mr. Gandhi's appointment hinges on approval from KRLL's shareholders at their upcoming Annual General Meeting. If approved, the subsidiary will gain significant funds for operational funding and a strengthened leadership team.

Investors will be monitoring the upcoming shareholder vote for approval and observing how KRLL utilizes the new funds to enhance its operations.